Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 7 June 2024 AM
Pfizer has accused Samsung Bioepis of fishing for reasons to invalidate a patent in its legal stoush against the top-earning biosimilar in Australia.
Samsung Bioepis launched its Enbrel biosimilar, Brenzys, in Australia in 2017, and in the financial year ending June 2023 it was the highest earning biosimilar brand listed on the PBS. Enbrel and Brenzys earned a combined $101.2 million for the financial year 2023, with the biosimilar Brenzys earning $41.8 million of that.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.